These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

886 related items for PubMed ID: 9635673

  • 1. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ.
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [Abstract] [Full Text] [Related]

  • 2. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D.
    Eur J Gynaecol Oncol; 2001 Jun; 22(2):122-6. PubMed ID: 11446475
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma.
    Vang R, Barner R, Wheeler DT, Strauss BL.
    Int J Gynecol Pathol; 2004 Jul; 23(3):223-33. PubMed ID: 15213598
    [Abstract] [Full Text] [Related]

  • 4. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ.
    Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
    [Abstract] [Full Text] [Related]

  • 5. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, Lu KH.
    Cancer Res; 2003 Oct 01; 63(19):6195-9. PubMed ID: 14559803
    [Abstract] [Full Text] [Related]

  • 6. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF, Kurman RJ.
    Verh Dtsch Ges Pathol; 1997 Oct 01; 81():228-32. PubMed ID: 9474874
    [Abstract] [Full Text] [Related]

  • 7. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
    Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE.
    Int J Surg Pathol; 2004 Jul 01; 12(3):207-23. PubMed ID: 15306933
    [Abstract] [Full Text] [Related]

  • 8. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.
    Am J Surg Pathol; 2008 Feb 01; 32(2):304-15. PubMed ID: 18223334
    [Abstract] [Full Text] [Related]

  • 9. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct 18; 43(5):743-8. PubMed ID: 22008688
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI, Mesia AF, Mittal K, Vamvakas E.
    Int J Gynecol Pathol; 1999 Jul 18; 18(3):233-7. PubMed ID: 12092593
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH.
    Histopathology; 2014 Mar 18; 64(4):585-96. PubMed ID: 24103020
    [Abstract] [Full Text] [Related]

  • 12. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J, Yokoyama Y, Futagami M, Mizunuma H, Yoshioka H, Washiya K, Hana K, Endou H, Okayasu I.
    Int J Gynecol Cancer; 2014 May 18; 24(4):659-63. PubMed ID: 24694899
    [Abstract] [Full Text] [Related]

  • 13. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
    Sherman ME, Bur ME, Kurman RJ.
    Hum Pathol; 1995 Nov 18; 26(11):1268-74. PubMed ID: 7590703
    [Abstract] [Full Text] [Related]

  • 14. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.
    Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ.
    Hum Pathol; 1995 Nov 18; 26(11):1260-7. PubMed ID: 7590702
    [Abstract] [Full Text] [Related]

  • 15. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D, Socolov R, Lupascu IA, Rugina V, Gabia O, Garauleanu DM, Carauleanu A.
    Rev Med Chir Soc Med Nat Iasi; 2016 Nov 18; 120(2):355-62. PubMed ID: 27483717
    [Abstract] [Full Text] [Related]

  • 16. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA.
    Am J Surg Pathol; 2004 Dec 18; 28(12):1568-78. PubMed ID: 15577675
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB.
    Mod Pathol; 2002 Apr 18; 15(4):365-71. PubMed ID: 11950909
    [Abstract] [Full Text] [Related]

  • 19. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A, Köbel M, Kalloger SE, Gilks CB.
    Int J Gynecol Pathol; 2010 Jul 18; 29(4):343-50. PubMed ID: 20567148
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.